At T-Cypher Bio we generate novel TCR-based therapeutics that have the potential to transform the treatment of immune-mediated disease. Our proprietary platforms provide unique insight into T cell based immunity in both health and disease. High throughput, high-resolution profiling of the immune synapse enables us to map the intracellular target space and profile T cell specificity. These platforms not only give us tools to build highly innovative drugs, but also build immune system data sets of unprecedented size. These data sets support cutting edge computational modelling of T cell repertoires which will revolutionize T cell immunology.
To build our oncology pipeline, we validate novel, shared, tumour-specific targets and identify panels of rare functionally-defined T cell clones. The unique TCRs we identify are the foundation of our broad pipeline of lifesaving therapeutics for underserved solid tumour patients.
Company Details
- Employees
- 41
- Founded
- -
- Address
- Oxford, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://tcypherbio.com/
- Keywords
- jobs.
- HQ
- Oxford
T-Cypher Bio Questions
T-Cypher Bio's website is https://tcypherbio.com/
T-Cypher Bio's LinkedIn profile is https://uk.linkedin.com/company/t-cypher-bio
T-Cypher Bio has
41 employees.
View email and phone details for 41
employees at T-Cypher Bio.
T-Cypher Bio's industry is
Biotechnology Research
T-Cypher Bio's top competitors are
Scancell,
Immunocore,
Adaptimmune,
Enara Bio,
Theolytics,
Oxgene,
Oxb,
T-Therapeutics Ltd,
Orbit Discovery,
Etcembly Ltd.
T-Cypher Bio's categories are Biotechnology Research
T-Cypher Bio's founding year is 2021
